Referenser

  1. (SNEMA) SNA. Polyneuropati Vårdprogram  [updated 2023-12; cited 2024 07-08]. Available from: https://www.snema.se/dokument.html

  2. Hughes R. Peripheral nerve diseases: the bare essentials. Pract Neurol. 2008;8(6):396-405.

  3. Callaghan BC, Price RS, Feldman EL. Distal Symmetric Polyneuropathy: A Review. Jama. 2015;314(20):2172-81.

  4. Overell JR. Peripheral neuropathy: pattern recognition for the pragmatist. Pract Neurol. 2011;11(2):62-70.

  5. (IHS) HCCotIHS. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.

  6. Maarbjerg S, Di Stefano G, Bendtsen L, Cruccu G. Trigeminal neuralgia - diagnosis and treatment. Cephalalgia. 2017;37(7):648-57.

  7. Olesen J. International Classification of Headache Disorders. Lancet Neurol. 2018;17(5):396-7.

  8. Olesen J. International Classification of Headache Disorders. Lancet Neurol. 2018;17(5):396-7.

  9. Hans G, Sabatowski R, Binder A, Boesl I, Rogers P, Baron R. Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Curr Med Res Opin. 2009;25(5):1295-305.

  10. Navez ML, Monella C, Bösl I, Sommer D, Delorme C. 5% Lidocaine Medicated Plaster for the Treatment of Postherpetic Neuralgia: A Review of the Clinical Safety and Tolerability. Pain Ther. 2015;4(1):1-15.

  11. Lambru G, Zakrzewska J, Matharu M. Trigeminal neuralgia: a practical guide. Pract Neurol. 2021;21(5):392-402.

  12. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.

  13. Carrazana E, Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J Pain Symptom Manage. 2003;25(5 Suppl):S31-5.

  14. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet. 2009;374(9697):1252-61.

  15. Läkemedelsbehandling av långvarig smärta hos barn och vuxna – behandlingsrekommendation. Information från Läkemedelsverket. 2017;28(3):23-53.

  16. Eviston TJ, Croxson GR, Kennedy PG, Hadlock T, Krishnan AV. Bell's palsy: aetiology, clinical features and multidisciplinary care. J Neurol Neurosurg Psychiatry. 2015;86(12):1356-61.

  17. de Almeida JR, Guyatt GH, Sud S, Dorion J, Hill MD, Kolber MR, et al. Management of Bell palsy: clinical practice guideline. Cmaj. 2014;186(12):917-22.

  18. Knudtzen FC, Andersen NS, Jensen TG, Skarphédinsson S. Characteristics and Clinical Outcome of Lyme Neuroborreliosis in a High Endemic Area, 1995-2014: A Retrospective Cohort Study in Denmark. Clin Infect Dis. 2017;65(9):1489-95.

  19. Behandlingsrekommendation: Antibiotika vid borreliainfektion Uppsala: Läkemedelsverket; Juni 2024.

  20. Stupica D, Bajrović FF, Blagus R, Cerar Kišek T, Collinet-Adler S, Lah A, et al. Clinical manifestations and long-term outcome of early Lyme neuroborreliosis according to the European Federation of Neurological Societies diagnostic criteria (definite versus possible) in central Europe. A retrospective cohort study. Eur J Neurol. 2021;28(9):3155-66.

  21. Mygland A, Ljøstad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol. 2010;17(1):8-16, e1-4.

  22. Kortela E, Kanerva MJ, Puustinen J, Hurme S, Airas L, Lauhio A, et al. Oral Doxycycline Compared to Intravenous Ceftriaxone in the Treatment of Lyme Neuroborreliosis: A Multicenter, Equivalence, Randomized, Open-label Trial. Clin Infect Dis. 2021;72(8):1323-31.

  23. Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology. 1994;44(7):1203-7.

  24. Dersch R, Rauer S. Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis: An updated systematic review. Eur J Neurol. 2023;30(12):3780-8.

  25. Dotevall L, Hagberg L. Penetration of doxycycline into cerebrospinal fluid in patients treated for suspected Lyme neuroborreliosis. Antimicrob Agents Chemother. 1989;33(7):1078-80.

  26. Jowett N, Gaudin RA, Banks CA, Hadlock TA. Steroid use in Lyme disease-associated facial palsy is associated with worse long-term outcomes. Laryngoscope. 2017;127(6):1451-8.

  27. Marques A, Okpali G, Liepshutz K, Ortega-Villa AM. Characteristics and outcome of facial nerve palsy from Lyme neuroborreliosis in the United States. Ann Clin Transl Neurol. 2022;9(1):41-9.

  28. Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011;18(1):5-18.

  29. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863-73.

  30. Albanese A, Barnes MP, Bhatia KP, Fernandez-Alvarez E, Filippini G, Gasser T, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol. 2006;13(5):433-44.

  31. Bohn E, Goren K, Switzer L, Falck-Ytter Y, Fehlings D. Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta-analysis. Dev Med Child Neurol. 2021;63(9):1038-50.

  32. Reese R, Volkmann J. Deep Brain Stimulation for the Dystonias: Evidence, Knowledge Gaps, and Practical Considerations. Mov Disord Clin Pract. 2017;4(4):486-94.

  33. Marsden J, Stevenson V, Jarrett L. Treatment of spasticity. Handb Clin Neurol. 2023;196:497-521.

  34. Chang E, Ghosh N, Yanni D, Lee S, Alexandru D, Mozaffar T. A Review of Spasticity Treatments: Pharmacological and Interventional Approaches. Crit Rev Phys Rehabil Med. 2013;25(1-2):11-22.

  35. Thompson AJ, Jarrett L, Lockley L, Marsden J, Stevenson VL. Clinical management of spasticity. J Neurol Neurosurg Psychiatry. 2005;76(4):459-63.

  36. Williams G, Singer BJ, Ashford S, Hoare B, Hastings-Ison T, Fheodoroff K, et al. A synthesis and appraisal of clinical practice guidelines, consensus statements and Cochrane systematic reviews for the management of focal spasticity in adults and children. Disabil Rehabil. 2022;44(4):509-19.

  37. [Internet] SMS. Metodboken, MS, Symptomatisk behandling spasticitet 2021 [cited 2024 07-08]. Available from: https://www.mssallskapet.se/wp-content/uploads/2022/03/Spasticitet-.docx_211215.pdf

  38. Tedroff K. [Treatment of spasticity can improve everyday life]. Lakartidningen. 2013;110(15):762-4.

  39. Society S-SMD. Svenska riktlinjer för utredning och behandling av tremortillstånd 2021 [updated 2021; cited 2024 07-08]. 2:[Available from: https://www.swemodis.se/wp-content/uploads/2021/03/Tremor-riktlinjer-2-revidering-2021-1.pdf

  40. Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, et al. Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018;33(1):75-87.

  41. [Internet] NIoNDaS. Tremor 2024 [updated 2024-05-15; cited 2024 07-10]. Available from: https://www.ninds.nih.gov/health-information/disorders/tremor

  42. Haubenberger D, Hallett M. Essential Tremor. N Engl J Med. 2018;378(19):1802-10.

  43. Louis ED. The Roles of Age and Aging in Essential Tremor: An Epidemiological Perspective. Neuroepidemiology. 2019;52(1-2):111-8.

  44. Zesiewicz TA, Elble RJ, Louis ED, Gronseth GS, Ondo WG, Dewey RB, Jr., et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology. 2011;77(19):1752-5.

  45. Iacono MI, Atefi SR, Mainardi L, Walker HC, Angelone LM, Bonmassar G. A Study on the Feasibility of the Deep Brain Stimulation (DBS) Electrode Localization Based on Scalp Electric Potential Recordings. Front Physiol. 2018;9:1788.

  46. Socialstyrelsen. ALS {Internet} 1998 [updated 2022-12-20; cited 2024 07-08]. Available from: https://www.socialstyrelsen.se/kunskapsstod-och-regler/omraden/sallsynta-halsotillstand/als/

  47. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-55.

  48. van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084-98.

  49. Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162-72.

  50. National Institute for Health and Care Excellence: Guidelines.  Motor neurone disease: assessment and management. London: National Institute for Health and Care Excellence (NICE) Copyright © NICE 2020.; 2019.

  51. Van Damme P, Al-Chalabi A, Andersen PM, Chiò A, Couratier P, De Carvalho M, et al. European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD). Eur J Neurol. 2024;31(6):e16264.

  52. Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol. 2005;12(12):921-38.

  53. Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360-75.

  54. Pirskanen-Matell R, Matell G, Kalb B, Bjelak S. [Myasthenia gravis--an autoimmune neuromuscular disease]. Lakartidningen. 2000;97(41):4594-8.

  55. Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570-81.

  56. [Internet] SNA. Myastenia Gravis (MG) Svenskt konsensusprogram 2024 2024 [updated 2024; cited 2024 07-08]. Available from: https://www.snema.se/dokument_files/MGkonsensus2024v2.pdf

  57. Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114-22.

  58. Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, et al. Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. JAMA Neurol. 2022;79(11):1105-12.

  59. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol. 2019;18(3):259-68.

  60. van Doorn PA, Van den Bergh PYK, Hadden RDM, Avau B, Vankrunkelsven P, Attarian S, et al. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome. Eur J Neurol. 2023;30(12):3646-74.

  61. Jacobs BC, van den Berg B, Verboon C, Chavada G, Cornblath DR, Gorson KC, et al. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. J Peripher Nerv Syst. 2017;22(2):68-76.

  62. Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671-83.

  63. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717-27.

  64. Press R, Askmark H, Andersen O. [Inflammatory polyneuropathies can be treated successfully]. Lakartidningen. 2012;109(19):950-4.

  65. Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021;26(3):242-68.

  66. {Internet} SNA. CIDP nationellt konsensus om diagnostik och behandling från SNEMA 2023 2023 [cited 2024 07-08]. Available from: https://www.snema.se/dokument_files/CIDP%20konsensus%20Diagnostik%20och%20behandling_2023.pdf

  67. Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019;18(8):784-94.

  68. [Internet] S. Kronisk inflammatorisk demyeliniserande polyneuropati 2001 [updated 2023-06-27; cited 2024 07-08]. Available from: https://www.socialstyrelsen.se/kunskapsstod-och-regler/omraden/sallsynta-halsotillstand/kronisk-inflammatorisk-demyeliniserande-polyneuropati/

Föregående sida
Kronisk inflammatorisk demyeliniserande polyneuropati

Nästa sida
Tillbaka till kapitlets första sida